Replies to post #194462 on Biotech Values

[maverick_1]

OMER re aHUS #2..

If these guys were selling because they were scared of OMER's project, they would have stepped up and bought OMER at some point during the recent weakness.

Despite the massive short term decline since say mid Spring, embedded within those days were very significant buying most especially during the last five trading days prior to today's action that I observed with some relief. However it undoubtedly sorely tested one's faith in OMER as clearly the selling almost appeared relentless and overcame every buying surge. Although OMER has had long term success although under siege with shorts,I fortunately held tight. And it is only because of CEO and IP maven Gregory A. Demopulos, M.D Phd Stanford grad is why I invested in OMER.

There are a lot of players that tend to short biotech stocks where they believe a recently approved product will show an anemic growth pattern for the first several quarters. Likely most of those guys have never even heard of aHUS and got blindsided here.

FYI over the last year plus, there have been many OMER research reports that do cite specifically Alexions Soliris re aHUS. Admittedly for most investors, OMER is complex with it's 12 programs. But not to notice the POSSIBLE potential of aHUS would be improper due diligence and especially for those brazen shorts: 25% short of the outstanding shares.